Table 1. Summary of the eight included studies.

Study	Origin of population	Study design	Disease	N	Stage	TUG1 assay	Survival analysis	Metastasis analysis	Hazard ratios	Follow-up Months
Zhang 2014 [13]	China	R	NSCLC	192	I/II, III/IV	qRT-PCR	OS	LNM	K-M	60
Tan 2015 [14]	China	R	BC	54	I–IV	qRT-PCR	OS	NA	K-M	60
Zhang 2016 [19]	China	R	GC	100	I/II, III/IV	qRT-PCR	OS	LNM/DM	K-M/HR	60
Sun 2016 [18]	China	R	CC	120	NA	qRT-PCR	OS	LNM	K-M	60
Ma 2016 [17]	China	R	OSA	76	I/II, III/IV	qRT-PCR	OS, PFS	IM	K-M/HR	60
Jiang 2016 [15]	China	R	ESCC	218	I/II, III/IV	qRT-PCR	OS	LNM	K-M/HR	80
Iliev 2016 [16]	Czech Republic	R	BC	47	I/II, III/IV	qRT-PCR	OS	DM	K-M	150
Niu 2017 [20]	China	R	SCLC	33	NA	qRT-PCR	OS	NA	K-M	30

Study design is described as retrospective (R); OSA, osteosarcoma; GC, gastric cancer; BC, bladder cancer; CC, colorectal cancer; SCLC, small cell lung cancer; NSCLC, Non small cell lung cancer; ESCC, esophageal squamous cell carcinoma; DM, distant Metastasis; LNM, Lymph Node Metastasis; IM, Initial metastasis